BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34708436)

  • 21. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of donor-recipient combinational CYP3A5 genotypes on tacrolimus dosing in Chinese DDLT adult recipients.
    Liu J; Chen D; Yao B; Guan G; Liu C; Jin X; Wang X; Liu P; Sun Y; Zang Y
    Int Immunopharmacol; 2020 Mar; 80():106188. PubMed ID: 31931373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
    Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
    Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
    Li DY; Teng RC; Zhu HJ; Fang Y
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of tacrolimus and Wuzhi tablet pharmacokinetic interaction magnitude in renal transplant recipients.
    Chen P; Dai R; She Y; Fu Q; Huang M; Chen X; Wang C
    Clin Transplant; 2022 Dec; 36(12):e14807. PubMed ID: 36057787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
    Gómez-Bravo MA; Apellaniz-Ruiz M; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Bilbao I; Alamo JM; Millán O; Brunet M; Rodríguez-Antona C
    Pharmacogenet Genomics; 2018 Feb; 28(2):41-48. PubMed ID: 29256966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
    Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
    Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.
    Calvo PL; Serpe L; Brunati A; Nonnato A; Bongioanni D; Olio DD; Pinon M; Ferretti C; Tandoi F; Carbonaro G; Salizzoni M; Amoroso A; Romagnoli R; Canaparo R
    Br J Clin Pharmacol; 2017 Jun; 83(6):1252-1262. PubMed ID: 28044353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Artificial Neural Network Analysis of Determinants of Tacrolimus Pharmacokinetics in Liver Transplant Recipients.
    Du Y; Zhang Y; Yang Z; Li Y; Wang X; Li Z; Ren L; Li Y
    Ann Pharmacother; 2024 May; 58(5):469-479. PubMed ID: 37559252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.
    Pinon M; De Nicolò A; Pizzol A; Antonucci M; D'Avolio A; Serpe L; Dell'Olio D; Catalano S; Tandoi F; Romagnoli R; Canaparo R; Calvo PL
    Sci Rep; 2021 Jan; 11(1):443. PubMed ID: 33432012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
    Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
    Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.
    Xue F; Han L; Chen Y; Xi Z; Li Q; Xu N; Xia Y; Streicher K; Zhang J; Xia Q
    Pediatr Transplant; 2014 Mar; 18(2):166-76. PubMed ID: 24438215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of hepar-protecting Wuzhi capsule on pharmacokinetics and dose-effect character of tacrolimus in healthy volunteers.
    Teng F; Wang W; Zhang W; Qu J; Liu B; Chen J; Liu S; Li M; Chen W; Wei H
    Biopharm Drug Dispos; 2022 Aug; 43(4):119-129. PubMed ID: 35180322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients.
    Teng F; Zhang W; Wang W; Chen J; Liu S; Li M; Li L; Guo W; Wei H
    Biopharm Drug Dispos; 2022 Apr; 43(2):76-85. PubMed ID: 35220592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
    Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
    Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.
    Ji E; Choi L; Suh KS; Cho JY; Han N; Oh JM
    Transplantation; 2012 Oct; 94(8):866-72. PubMed ID: 22992768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.